These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. Kashef N, Behzadian-Nejad Q, Najar-Peerayeh S, Mousavi-Hosseini K, Moazzeni M, Djavid GE. J Med Microbiol; 2006 Oct; 55(Pt 10):1441-1446. PubMed ID: 17005795 [Abstract] [Full Text] [Related]
6. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. Bruderer U, Cryz SJ, Schaad UB, Deusinger M, Que JU, Lang AB. J Infect Dis; 1992 Aug; 166(2):344-9. PubMed ID: 1634805 [Abstract] [Full Text] [Related]
13. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. Wessels MR, Paoletti LC, Pinel J, Kasper DL. J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814 [Abstract] [Full Text] [Related]
14. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Lee NG, Jung SB, Ahn BY, Kim YH, Kim JJ, Kim DK, Kim IS, Yoon SM, Nam SW, Kim HS, Park WJ. Vaccine; 2000 Mar 17; 18(18):1952-61. PubMed ID: 10699346 [Abstract] [Full Text] [Related]
18. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Hemachandra S, Kamboj K, Copfer J, Pier G, Green LL, Schreiber JR. Infect Immun; 2001 Apr 17; 69(4):2223-9. PubMed ID: 11254577 [Abstract] [Full Text] [Related]
19. Conjugate vaccines against Pseudomonas aeruginosa and malaria. Cryz SJ, Sadoff JC, Que JU. Contrib Microbiol Immunol; 1989 Apr 17; 10():166-89. PubMed ID: 2510972 [No Abstract] [Full Text] [Related]